TMS denied as not FDA-approved for this use by Cigna?

Cigna's specific coverage criteria for tms are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna May Deny TMS as "Not FDA-Approved"

This denial reason is frequently incorrect as applied to TMS, and that makes it one of the more straightforward to appeal. TMS devices have received FDA clearance for specific indications, including Major Depressive Disorder and Obsessive-Compulsive Disorder, among others. If Cigna's denial states TMS is not FDA-approved, the denial may reflect a documentation gap (the claim does not clearly specify the FDA-cleared indication), a confusion between the cleared indication and an off-label use, or an administrative error. The first step is determining exactly which indication your provider is treating and whether it corresponds to an FDA-cleared TMS indication.

## Your Appeal Rights

Federal law under ACA §2719 and ERISA §503 guarantees your right to a full internal appeal followed by an independent external review if internal appeal is denied. The external review is binding on Cigna and is conducted by an accredited, independent organization. You typically have approximately 180 days from receipt of a denial to file your internal appeal. Expedited review is available if waiting for a standard-track decision would seriously jeopardize your health or ability to function.

## What to Gather

• FDA clearance documentation: Your prescribing clinician or TMS provider can supply the FDA 510(k) clearance documentation for the specific device being used and the specific indication for which you are being treated.
• Indication alignment letter: A letter from your clinician confirming that your diagnosis matches the FDA-cleared indication and that the proposed use is consistent with that clearance.
• Cigna's policy language: Obtain Cigna's current TMS coverage policy and confirm exactly what FDA-approval language they cite — whether they are relying on an outdated policy or applying an incorrect standard.
• Chart documentation: Diagnosis records, clinical notes, and severity documentation that link your condition to the cleared indication.

## Criteria-Mapping Structure

Organize your appeal response around each element Cigna used to support the "not FDA-approved" determination:

| Cigna's Basis | Your Rebuttal Evidence | |---|---| | Assertion that TMS is not FDA-approved | FDA clearance documentation for device and indication | | Specific indication cited in denial | Clinician letter confirming your diagnosis matches cleared indication | | Cigna policy language used | Current Cigna policy vs. actual FDA clearance status |

If TMS is being used for an off-label indication in your case, the framing shifts — acknowledge the off-label use and redirect the appeal toward the medical-necessity and clinical evidence pathway rather than FDA clearance.